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 Abstract: 
Introduction: It is known that there is an association between higher body mass index (BMI) and 
lower extremity osteoarthritis (OA), but the presence of this degenerative disease in the shoulder 
remains relatively unknown. Adipokines, cytokines at increased concentrations in higher body 
mass index (BMI) individuals play a role in cartilage degeneration providing a plausible link 
between BMI and glenohumeral OA. We examined the association between BMI and the 
prevalence of glenohumeral OA and arthroplasty. 
 
Methods: This retrospective cohort study compared 596,874 age and gender matched patients 
across six BMI cohorts from a private payer database (Humana). The prevalence of 
glenohumeral OA was determined in each cohort, as was the standardized arthroplasty rates. 
Odds ratios were calculated for both OA and standardized arthroplasty rates by comparing the 
reference cohort, BMI < 19, cohort to the other five BMI cohorts.  
 
Results: Individuals in the five cohorts above the BMI < 19 level were all at increased odds of 
developing glenohumeral OA compared to those in the BMI < 19 cohort (OR range: 1.21 – 
1.92). Those in the three cohorts above BMI 30 were also at increased odds of undergoing 
arthroplasty (OR range: 1.19 – 1.52) compared with the reference standard. 
 
Conclusions: Patients with higher BMI are at increased odds of developing glenohumeral OA, 
despite the conventional belief that such an association is limited to hip and knee joints.  
Additionally, the previously unreported finding of an increased rate of arthroplasty performed on 
 obese patients represents a novel source of a disproportionately high surgical burden among this 
segment of the population. 
 
Abstract word count: 252 
  
 Introduction: 
Osteoarthritis (OA) and obesity are widely recognized as two integrally associated 
pathologies. The classic model of their relationship states that increasing body weight places a 
proportionally greater degree of mechanical stress on weight-bearing joints, leading to the 
development and progression of primary OA1. Increased prevalence of OA of the hip and knee in 
obese individuals is consistent with this theory2-5. Recent research into obesity, however, has 
demonstrated that excess adipose tissue exerts an additional influence beyond the forces its mass 
applies to the body’s susceptible joints. By a variety of mechanisms. obesity also induces a state 
of chronic, low-grade inflammation6 with evidence of multiple systemic proinflammatory 
factors7. Adipokines (adipose tissue-secreted cytokines) are one such factor that has recently 
been shown to contribute to the pathophysiology of OA affecting both cartilage loss8 and pain9-
11. In an attempt to understand the relative importance of the mechanical effects of obesity versus 
the systemic inflammatory effects, we attempted to study a large joint classically described as 
“non-weight bearing”—the glenohumeral joint. 
 
Osteoarthritis: 
Osteoarthritis is the leading cause of disability among American adults, affecting 22.7% 
of the population12,13. As such, it costs approximately $80.8 billion in direct medical costs, and 
$47 billion in indirect costs such as lost productivity14. Although the exact pathogenesis of OA 
continues to evolve, a variety of risk factors have been identified that affect gross and 
histological changes to cartilage tissue. Patients at increased risk include females, the elderly, 
obese individuals, and those with genetic predispositions5,15. Among individuals with these risk 
factors, the typical composition of articular cartilage – type II collagen and proteoglycans – will 
 begin to pathologically degrade. As a result, chondrocytes, the tissue’s sole cell type, will cluster, 
undergo hypertrophy, and secrete enzymes that breakdown the extracellular matrix, ultimately 
destroying the cartilage. This process progresses and ultimately results in the morbidity of 
increasing pain and decreasing range of motion16.  
 
The glenohumeral joint is a relatively uncommon location for OA and may have an 
prevalence as much as 300 times lower than the 45% prevalence that is routinely reported for 
knee OA17. While significantly rarer than hip, knee, and hand OA, glenohumeral OA nonetheless 
represents a significant burden of disease3,5. First-line management for this disease is often 
defined by some combination of nonsteroidal anti-inflammatory drugs, activity modification, 
corticosteroid injections and physical therapy, all of which may improve pain and function to 
some degree18. However, given that these conservative, symptom-managing treatments do not 
modify the progression of the underlying disease, the decision to perform surgery is often made 
when the pain and loss of function have progressed to the point of warranting a change3. 
 
Multiple operative approaches are used in treating glenohumeral OA that is refractory to 
nonoperative treatment. In the category of arthroplasty procedures for OA are hemiarthroplasty, 
total shoulder arthroplasty, and reverse total shoulder arthroplasty – each of which has its own 
short, mid and long-term success rates and complications.3 
 
Obesity:  
Obesity is a well-established concern in the United States with an estimated prevalence of 
36.5% of all adults19 and an annual cost of $147 billion in medical spending. This amounts to 
 42% more per capita medical spending than that which is spent on non-obese individuals20. The 
source of this increased spending is largely derived from obesity’s relationship to diabetes, 
dyslipidemia, atherosclerosis21 and the resultant increased risk of stroke and cardiovascular 
disease7.  
 
The wide-ranging effects of obesity are, in part, secondary to the numerous, 
proinflammatory immunological changes that occur in adipose tissue of those with obesity21. For 
example, higher circulating levels of lipopolysaccharides and free fatty acids both result in 
macrophage infiltration of adipose tissue6,22. Accompanying these macrophages are neutrophils, 
mast cells, B- and some subsets of T-lymphocytes as eosinophil and Th2 cell counts decline7. 
Obesity also contributes to the relative underperfusion and subsequent hypoxia of adipose as the 
amount and metabolism of this tissue increases6,23. Thus, as the physiological equilibrium of 
immune cells in fat tissue is perturbed, the initially-local inflammation results in increased 
synthesis of proinflammatory cytokines, namely leptin, adiponectin, TNF-α, IL-6, and monocyte 
chemoattract protein-1 (MCP1)7,24,25, and the systemic inflammatory state is produced and 
perpetuated7. When these proteins are disseminated throughout the body, they exert their effects 
on the body’s tissues, adding an additional, chronic inflammatory stressor on joints not 
encountered by non-obese individuals. 
 
Obesity and Osteoarthritis: 
As two widely prevalent diseases, the interplay between obesity and OA has been well 
studied. In American adults who are normal or underweight, the prevalence of OA is 
approximately 16%, which increases to 23% among overweight adults, and 31% for obese 
 individuals15. In fact, the previously cited statistic of a 45% lifetime risk for developing 
symptomatic knee OA increases to 60.5% among obese individuals17. This relationship is further 
corroborated by studies demonstrating a decreased risk of symptomatic OA among patients who 
lose weight, and an increase among those who gain weight26.  
 
As a known risk factor for OA, researchers have postulated how excess adipose tissue 
contributes to this degenerative pathology. Mechanical models, such as changes in joint 
biomechanics27 have prevailed historically, but the recent focus on adipokines helps to broaden 
the understanding of obesity’s effects, particularly on non-weight-bearing joints where obesity-
induced mechanical forces theoretically have less of an effect28-31. 
 
Among the adipokine class of cytokines, leptin, adiponectin, resistin, and IL-6 have 
received the most attention. Both IL-6 and leptin have been associated with the loss of cartilage 
and the development of knee OA8,32,33, but this effect has been understudied in the glenohumeral 
joint. In a study of South Koreans over age 65, obesity was found to be significantly associated 
with spine and knee OA with odds ratios (OR) of 1.5 and 3.4 respectively. This same study also 
found an OR of 1.7 for shoulder OA that was not statistically significant; however, the study was 
underpowered to detect a difference for shoulder OA (only 36 subjects of 1,118- sampled had 
shoulder OA)34. In 2012, Gandhi, et al. wrote a letter to the editor in which they demonstrate that 
adipokines – primarily leptin – are present in shoulder synovial fluid in a group of patients with a 
mean BMI of 28.3 kg/m2, however their study was limited by a cross-sectional design and a lack 
of a control group of normal weight individuals35. This letter was followed by an article in 2013 
 in which they demonstrated that higher leptin and adiponectin levels in shoulder synovial fluid 
were associated with higher patient-reported pain scores28. 
 
Our purpose is to define the prevalence of shoulder OA in obese and non-obese 
populations, as well as to understand the rate and type of shoulder arthroplasty procedures 
performed across BMI categories – to the best of our knowledge, the first such analysis on this 
topic. Despite the fact that the shoulder is a “non-weight bearing joint”28-31 and thus should not 
be as susceptible as the knee4 and hip2 to the increased mechanical forces secondary to obesity, 
we hypothesize that the obese state will still lead to an increased prevalence of shoulder OA, 
particularly bilateral OA, and a greater number of shoulder arthroplasties when compared with 
non-obese individuals. 
 
Methods: 
This retrospective review was conducted using the database of the private payer Humana 
from 2007-2016 quarter 3 (q3) and was accessed with the PearlDiver Technologies user interface 
(Warsaw, IN, USA). This database contains claims information from over 23.5 million patients 
with an orthopaedic diagnosis in that time period. This study was considered exempt from 
further review by our Institutional Review Board.  
 
The database was queried for body mass index (BMI) using International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-9) diagnosis codes for BMI under 19 
kg/m2 to BMI over 39 kg/m2 in 5 kg/m2 increments. ICD-10 codes were also used for 2015 
quarter 4 (q4) to 2016q3 (Appendix).  Cases were grouped by BMI (under 19, 20-24, 25-29, 30-
 34, 34-39, over 39).  Since ICD-9 and ICD-10 both use integers to define BMI ranges, the 
customary threshold between underweight and normal BMI of 18.5 kg/m2 is coded as BMI <19 
and BMI 19-24, respectively. All cohorts were matched by age and gender using PearlDiver 
command language, resulting in six cohorts of 99,479 patients each with identical age and gender 
makeup. This preferentially selected for younger and female patients, especially among the 
lower-BMI cohorts. Charlson Comorbidity Index (CCI), a measure of 10-year predicted 
mortality, was also calculated for each matched group36.  
 
The prevalence of arthritis in each BMI cohort was attained using ICD-9 and ICD-10 
diagnosis codes for primary glenohumeral OA. To determine how many patients with shoulder 
OA underwent shoulder arthroplasty – reverse total shoulder arthroplasty (RTSA), 
hemiarthroplasty (HA), and total shoulder arthroplasty – in each BMI cohort, ICD-9 and ICD-10 
procedure codes were used. Current Procedural Terminology (CPT) codes were not used 
because there is no code that identifies RTSA specifically. When comparing BMI cohorts for OA 
and arthroplasty incidence, odds ratios and 95% confidence intervals were calculated with α = 
0.05. The BMI < 19 cohort was used as the reference cohort in analysis to more comprehensively 
assess the spectrum of potentially increased risk of OA and arthroplasty across all BMI cohorts, 
including the normal, BMI 19-24 cohort. CCI scores were grouped into values of 0, 1, 2 and at 
least 3 and Pearson’s Chi-Square was tested across all six BMI cohorts. Arthroplasty rates were 
calculated by dividing the number of shoulder arthroplasties performed in each BMI cohort by 
the number of patients in each respective cohort who have glenohumeral OA, thus standardizing 
the rates across cohorts and minimizing any potential effect that changes in OA rates may have 
on arthroplasty rates. 
  
Results: 
 Of the 2,748,702 patients with a BMI diagnosis code in the Humana database, 596,874 
were able to be matched by age and gender into BMI cohorts so that each cohort had the same 
proportion of each age and gender group. Collectively, these age- and gender-matched BMI 
cohorts make up the primary cohort of this study. Of the primary cohort, 27,803 (4.66%) had a 
diagnosis of primary glenohumeral OA. The BMI cohorts had statistically different CCI scores, 
(P < 0.001) indicating each BMI cohort has a different average health status and 10-year 
estimated mortality (Table 1). 
 
Since the matched BMI < 19 group had the lowest proportion of shoulder OA, the 
prevalence in all other groups was compared to this cohort (Table 1). Glenohumeral OA was 
present in 3.76% of patients in the BMI 19-24 cohort versus 3.14% of patients in the BMI < 19 
cohort (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.15-1.27; P < 0.001), 4.40% of 
patients in the BMI 25-29 cohort (OR, 1.42; CI, 1.36-1.49; P < 0.001), 5.11% of patients in the 
BMI 30-34 cohort, (OR, 1.66; CI, 1.59-1.74; P < 0.001), 5.68% of patients in the BMI 35-39 
cohort (OR, 1.86; CI, 1.78-1.94; P < 0.001), and 5.86% of patients in the BMI > 39 cohort (OR, 
1.92; CI, 1.84-2.01; P < 0.001). 
 
Of patients with glenohumeral OA, the standardized rate of shoulder arthroplasty of the 
BMI < 19 cohort (7.02%) was not different from the BMI 19-24 cohort’s rate of 6.84% (P = 
0.787) or the BMI 25-29 cohort’s rate of 7.51% (P = 0.430). However, the cohorts with greater 
BMI did have higher standardized rates of arthroplasty; 8.23% of patients in the BMI 30-34 
 cohort underwent shoulder arthroplasty, significantly higher than in the BMI < 19 cohort (OR, 
1.19; CI, 1.00-1.41; P = 0.048). Similarly, the 10.45% standardized rate in the BMI 35-39 cohort 
demonstrated a statistically significant OR of 1.54 (CI, 1.31-1.82; P < 0.001) when compared to 
the reference cohort, as did the standardized rate of the BMI > 39 cohort, 10.28% (OR, 1.52; CI, 
1.29-1.78; P < 0.001). 
 
Discussion: 
We hypothesized that the prevalence of glenohumeral OA and rate of shoulder 
arthroplasty would increase as patient BMI increased. To test this hypothesis, we mined nine 
years of data from a large insurance database for patients with a recorded BMI and filtered six 
cohorts of these individuals by a diagnosis of glenohumeral OA and subsequent arthroplasty. The 
overall prevalence of glenohumeral OA was 4.66%. There was a small but significant and 
progressive increase in OA prevalence with increased BMI.  
 
The fact that there exists an association between obesity and OA in what has customarily 
been described as a “non-weight-bearing joint”28-31 requires considering mechanisms beyond the 
traditional mechanical forces model of OA, especially that glenohumeral OA is more the result 
of the chronic, systemic inflammatory state of obesity than the mechanical environment of the 
joint. As adipokines rise with accumulation of additional adipose tissue, leptin, which has been 
discovered in glenohumeral synovial fluid28,37, may be mediating increased cartilage 
destruction10,32,38,39.  
 
 Leptin has proven destructive effects on cartilage and local differences in leptin 
concentration suggest that all joints are not equally affected. Leptin simultaneously slows 
chondrocyte proliferation while stimulating the same cells to increase synthesis of the pro-
inflammatory molecules IL-1β, MMP-9 and MMP-1338. While increased leptin levels have been 
observed in the infrapatellar fat pad of obese individuals37,40,41, and thus posited as a mechanism 
for OA development in the adjacent knee joint, it is unclear whether the adipose tissue 
surrounding the shoulder behaves similarly. As our data show, however, even in the absence of 
this fat pad that theoretically influences the knee joint, the shoulder will nonetheless suffer 
higher OA rates in individuals with more overall adipose tissue. 
 
In addition, we found that the increased standardized rates of shoulder arthroplasty 
among patients with glenohumeral OA was greater in patients with higher BMI levels. All BMI 
cohorts over 30 kg/m2 demonstrated significantly greater odds of having this procedure than our 
referent (BMI < 19). To attempt to contextualize this finding, we note the reason why the 
decision to progress to operative management is often made: failure of conservative therapy, 
often manifesting as refractory or increased pain.  
 
One plausible explanation for why higher BMI patients may experience this worsened 
pain is the concurrent upregulation of central NMDA receptors and enhanced excitation of the 
same pathway in the presence of leptin11. It is possible that at increased plasma leptin levels, as 
seen in the obese patient32, the central nervous system of the higher BMI patient is modulated in 
such a fashion, thus predisposing the patient to the resultant sensitivity to neuropathic pain. As 
highlighted by Gandhi et al, shoulder OA pain may present as constant, dull and aching pain or 
 as what is presumed to be neuropathic pain, characterized as fleeting, but both physically and 
emotionally intense9,28. Gandhi and his colleagues further noted that synovial fluid leptin 
concentrations were predictive of scores on the short form of the McGill Pain Questionnaire (a 
patient-reported questionnaire for evaluating pain intensity, quality and behavior), further 
reinforcing the leptin-pain hypothesis. Thus, the increased arthroplasty rates among the higher 
BMI cohorts may be a function of this modified pain pathway and potentially may have 
significant therapeutic implications.  
 
Evidence exists for treating OA pain as, at least in part, neuropathically mediated, with 
serotonin-norepinephrine reuptake inhibitors, primarily42-45, but also venlafaxine46, both showing 
effect. Indeed, the strength of evidence for duloxetine’s pain-reducing effect was sufficient 
enough that it is now FDA-approved for this indication47. Similarly, two other neuromodulators 
in gabapentin48 and lacosamide49,50 have been successfully used to treat the pain of OA. Despite 
the evidence that treating OA pain centrally has potential, we are unaware of any studies that 
have focused on the effect of these medications in the obese population, where their effect may 
be more poignant given the potential sensitization to this type of pain in this group.  
 
The ultimate potential benefit of this finding is the opportunity to prolong the time, or 
considerably reduce the need, to perform arthroplasty in this segment of the population that 
experience glenohumeral OA at this increased rate. If the exact mechanisms by which obesity 
gives rise to these higher operative rates can be elucidated, then there is potential for adding a 
new line of medical management to the standard of care in overweight and obese patients with 
OA. In the same vein, recommending weight loss among the obese OA patient population as a 
 specific means of treating their OA, even glenohumeral OA, may also prove to beneficial. Future 
studies that research the effect of adding anticonvulsant or antidepressant drugs to the therapeutic 
regimen prescribed to the obese OA patient would serve well to answer the question of this 
approach’s efficacy. 
 
This study was not without limitations. By accessing an existing database of insurance 
claims through PearlDiver, we were limited to only data based on ICD-9 and ICD-10 codes, 
hindering our ability to analyze arthroplasty type more specifically or chart reviewing for 
additional information. The difference in CCI scores across BMI cohorts also presents a source 
of potential confounding. However, the increase seen in these scores at the extremes of the BMI 
ranges is not entirely unexpected, as underweight and obese individuals generally tend to be 
more ill. Given that our cohorts were already age and gender matched, we controlled for the 
main risk factors that predispose individuals to OA, making it unlikely that any other 
comorbidity captured by the CCI scores would serve as a significant mediator of the BMI effect 
we found on OA rates. That said, residual confounding due to various clinical and demographic 
variables is still a potential bias. Another limitation was our inability to dictate the nature of the 
data captured for this database – for example, the lack of information on prescribed medications 
– makes it impossible for us to determine the effect that anti-neuropathic pain medication may 
have on arthroplasty rates. Future research that examines this effect may serve well to not only 
help patients with glenohumeral OA, but any obese or overweight OA patient. 
 
Despite these limitations, this study contributes to a better understanding of the adverse 
effects that obesity has on the prevalence of glenohumeral OA. Additionally, the previously 
 unreported finding of an increased rate of glenohumeral arthroplasty performed on overweight 
and obese patients represents a novel source of a disproportionately high surgical burden among 
this segment of the population.   
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 Table 1: Glenohumeral Osteoarthritis and Arthroplasty Prevalence and Odds Ratios by Body Mass Index Cohort 
 Body Mass Index (kg/m2) 
 <19 19-24 25-29 30-34 35-39 >39 
Cohort count (#) 99479 99479 99479 99479 99479 99479 
Mean CCI (SD) 3.31 (3.58) 2.40 (2.98) 2.46 (2.93) 2.73 (3.02) 3.03 (3.09) 3.44 (3.24) 
GH OA (%) 3119 (3.14) 3740 (3.76) 4380 (4.40) 5082 (5.11) 5648 (5.68) 5834 (5.86) 
Odds Ratio REF 1.21* 1.42* 1.66* 1.86* 1.92* 
(95%CI) REF (1.15 – 1.27) (1.36 – 1.49) (1.59 – 1.74) (1.78 – 1.94) (1.84 – 2.01) 
GH Arthro. (%) 219 (7.02) 256 (6.84) 329 (7.51) 418 (8.23) 590 (10.45) 600 (10.28) 
Odds Ratio REF 0.97 1.08 1.19* 1.54* 1.52* 
(95%CI) REF (0.81 – 1.17) (0.90 – 1.28) (1.00 – 1.41) (1.31 – 1.82) (1.29 – 1.78) 
BMI= Body Mass Index; CCI=Charlson Comorbidity Index; SD=standard deviation; GH OA=number of patients in 
cohort with glenohumeral osteoarthritis (% of cohort with GH OA); 95%CI= 95 % confidence interval; GH Arthro. 
= number of patients who underwent glenohumeral arthroplasty (% of patients with GH OA in the cohort who also 
underwent arthroplasty); REF = referent cohort for odds ratio calculations; * indicates significance at α=0.05 
  
 Appendix A: The efficacy of anti-neuropathic pain medications in managing osteoarthritis 
pain: A systematic review 
  
 Introduction: 
 For years, the management of osteoarthritis (OA) pain has been targeted towards the 
nociceptive pain component of this condition. It was not until recently that the neuropathic pain 
aspect of this degenerative disease1 was acknowledged by the Food and Drug Administration, 
with the approval of duloxetine2. As one of many medications that treated neuropathic pain, 
duloxetine represented one of the few other ways that clinicians were able to conservatively treat 
the pain of OA until additional research into the efficacy of other anti-neuropathic pain 
medications was conducted. While there remains a dearth of literature on this topic, some studies 
– both animal and clinical – have been published in recent years that offer support for the use of 
these medications to dampen this pathway and assist patients in pain control. The purpose of this 
systematic review is to evaluate the recent body of literature on the pain management in OA 
using medications with presumed anti-neuropathic pain mechanisms.    
 
Methods: 
 The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)3 
guidelines were used for this systematic review. This protocol was not registered with any 
database. 
 
Eligibility criteria:  
 Full eligibility criteria are summarized in Table 1. Studies were considered eligible if 
they: presented original data on pain reduction in OA using an anti-neuropathic pain medication. 
Only English-language articles that were published since the year 2000 were included. Both 
animal and clinical studies were considered eligible. Anti-neuropathic pain medications were 
 defined as any anti-epileptic or anti-depressant medications that may also have a theoretical 
benefit in reducing OA pain as suggested by the literature. No direct comparator was necessary; 
uncontrolled studies and both placebo-controlled and non-placebo, comparative studies were 
included. Pain reduction was the primary outcome of interest, defined as the presence or absence 
of statistically significant decreased pain, by any measure, in the experimental, anti-neuropathic 
pain medication group, relative to that group’s baseline and/or the placebo group.  
 
Information sources and search strategy: 
 MEDLINE was queried using the PubMed search engine to identify all studies that meet 
inclusion criteria. Search terms included: “arthritis,” “osteoarthritis,” “neuropathic,” “pain,” 
“medication,” “gabapentin,” “carbamazepine,” “lamotrigine,” “phenytoin,” “venlafaxine,” 
“paroxetine,” “citalopram,” “bupropion,” “amitriptyline,” “nortriptyline,” “desipramine,” 
“duloxetine,” and affiliated terms using the PubMed MeSH tool. This search was conducted on 
May 23, 2018 and includes all results published since 2000. Reference lists of included articles 
were also screened to identify any relevant articles not found in the database search. 
 
Study selection and data extraction: 
 Titles and abstracts from all sources were screened for eligibility by K.W.; full-text 
articles of abstracts marked as potentially relevant were screened against the same eligibility 
criteria. All screening was conducted using the online systematic review tool, Covidence 
(https://www.covidence.org). 
 Relevant data were abstracted from all included studies in terms of study characteristics, 
enrolled populations, interventions, comparators, and outcomes. Due to the wide variability in 
 tools used to measure pain reduction across these animal and clinical studies, data on this 
variable were extracted as dichotomous for both pain reduction relative to baseline and placebo. 
When possible, multiple timepoints were captured. Significance for the pain reduction measures 
was also extracted, as were any adverse effects of the anti-neuropathic pain medication noted in 
the results of these studies. 
 
Risk of bias and analysis: 
 We used the Cochrane tool4 for assessing risk of bias in randomized controlled trials 
(RCT) and the ROBINS-I tool5 for non-randomized studies. Given the expected small volume of 
literature on this topic, all studies that otherwise met eligibility criteria were included, regardless 
of their overall risk of bias. Results are summarized qualitatively. Due to the small and 
heterogenous body of literature meta-analysis was not appropriate.  
Results: 
Study selection and characteristics:  
 Following the removal of duplicates, 464 studies underwent title and abstract screening 
for eligibility and 56 of these were assessed during full-text review.  Of these studies, the most 
common reasons for exclusion was the study of non-OA patients or animals, followed using non-
pain reduction outcomes (Figure 1). Nine studies6-14 were included in our final analysis (Table 
2).  Four of the articles were RCTs6-9 and four articles were also animal studies7, 10, 11, 14. The 
most commonly studied medication was duloxetine, which was studied in five of the nine 
articles6, 8-10, 13. The overall bias of studies trended towards being low in all studies and is 
elaborated in Tables 3 and 4. 
 
 Outcomes data: 
 Duloxetine studied in five studies and was shown to be efficacious in reducing OA pain 
in humans and rats both from baseline and when compared to placebo6, 8-10, 13. In humans, the 
dose ranged from 60mg daily6 up to 120mg daily8, 9 and data were frequently captured over 12 
weeks to 16 weeks of follow-up6,13. The other serotonin-norepinephrine reuptake inhibitor, 
venlafaxine, was also studied in humans and was similarly found to reduce patient’s pain at the 
final, 12 week time point at doses up to 225mg daily12.  The final, and most recent, study of 
either of these two drugs was published in 2014 and was an animal study documenting 
significant pain reduction when duloxetine was compared to placebo and when the final 
timepoint was compared to baseline for pain at rest alone; comparing pain during locomotion 
between the baseline and final timepoints did not yield significant results10. 
 
 Two studies administered lacosamide to rats to determine its effect on controlling OA 
pain7, 11. In one study, a reduction in pain from baseline was documented at the final, 2 weeks 
post-OA induction, timepoint11 and in the other, only results comparing this drug to placebo were 
reported7. These investigators found that lacosamide, when administered on the days they 
evaluated pain (days 3, 7 and 14 post-OA induction) performed significantly better than placebo 
on days 3 and 7, but not day 14. Gabapentin was studied in only one included article, a single-
cohort study. This drug’s subcutaneous administration to rats was shown to significantly reduce 
their OA pain after approximately two weeks14. 
 
Discussion: 
  Consistent evidence from the literature supports the use of duloxetine in the human 
population to treat OA pain. Indeed, multiple randomized controlled trials in humans have 
documented this effect6, 8, 9. Despite its ability to help patients control their pain, duloxetine has 
potential adverse effects.  Studies have documented both significantly more adverse events in the 
duloxetine group than the placebo group6 and increased rates of study discontinuation in a 
similar fashion8. Further research is needed to assess the comparative efficacy, harms and 
tolerability of duloxetine against other conservatively used medications. 
 
Given the aforementioned increased rate of glenohumeral OA in patients at higher BMI 
levels and the proposed susceptibility to neuropathic pain in this same population, there may be 
increased benefit to prescribing a medication such as duloxetine specifically in these patients.  
Additional studies will need to be conducted to determine if the use of duloxetine, with otherwise 
proven, general efficacy in OA, should be considered first-line conservative therapy in the obese 
population. 
 
 The research on venlafaxine, lacosamide and gabapentin in OA remains sparse7, 11, 12, 14. 
More conclusive evidence is needed to determine whether these medications are routinely used 
in are effective in the general OA population, and also subpopulations of patients with high BMI. 
The current studies in this domain are promising and well-conducted, albeit largely not yet in the 
clinical trial phase. Further research into the mechanisms behind obesity-induced neuropathic 
pain sensitivity will be helpful in determining which of these drugs can provide the greatest 
benefit in OA patients. 
 
 Conclusions: 
 Duloxetine represents a valid approach to the management of OA pain in the general 
population. There is insufficient evidence regarding the use of venlafaxine, lacosamide (due to 
few studies assessing each medication), however existing studies show promising preliminary 
results. No studies assessing these medications were conducted in the obese population (or report 
on subpopulations defined by BMI); further research should assess this population specifically 
due to the potential susceptibility to neuropathic pain in those with high BMI.  As additional 
information is uncovered about the mechanisms behind neuropathic pain sensitivity in the obese 
population, a more personalized approach to managing OA pain in these patients may be 
developed. 
 
  
 Appendix A Table 2. Study Eligibility Criteria 
PICOTSS Inclusion Criteria Exclusion Criteria 
Populations Patients or animals with 
primary osteoarthritis 
Rheumatoid or other 
inflammatory arthritis 
Interventions Any anti-neuropathic pain 
medication 
All other medications 
Comparators No restrictions Not applicable 
Outcomes Pain reduction from baseline 
or when compared to placebo 
Non-pain related measures 
Timing Published after 2000 Published prior to 2000 
Settings No restrictions Not applicable 
Study Design Reporting original data; RCT, 
cohort study (with or without 
a control group), case-
control, cross-sectional, case 
study, case series, animal 
study 
Non-original data; editorial, 
letter, comment, review, 
meta-analysis 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
  
Appendix A Figure 1. PRISMA Flow Diagram 
    
Appendix A Table 3. Included Study Characteristics and Results 
  
 
Appendix A Table 4. Risk of Bias Assessment for Included Randomized Controlled Trials 
Study Information Cochrane Tool 
# Author name Year Sequence generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel for all 
outcomes 
Blinding of 
outcome 
assessors for all 
outcomes 
Incomplete 
outcome data 
for all 
outcomes 
Selective 
outcome 
reporting 
Other 
sources of 
bias 
6 Abou-Raya et al. 2012 high high high low low low low 
8 Chappell et al. 2011 low low low low low low low 
9 Chappell et al. 2009 low low low unclear low low low 
11 Rahman & Dickenson 2014 low low low low low low low 
  
Appendix A Table 5. Risk of Bias Assessment for Included Non-Randomized Controlled Trials 
# Author name Year 
Pre-intervention domain At-intervention domain Post-intervention domain 
Final 
judgment Bias due to 
confounding 
Bias in 
selection 
of participants 
into the study 
Bias in 
classification of 
interventions 
Bias due to 
deviations 
from 
intended 
interventions 
Bias due to 
missing data 
Bias in 
measurement 
of outcomes 
Bias in 
selection 
of the 
reported 
result 
7 Beyreuther et al. 2007 low low low low low low low low 
10 Ishikawa et al. 2014 low low low low low low low low 
12 Sullivan et al. 2009 low low low low low low low low 
13 Sullivan et al. 2009 low low low low low low low low 
14 Vonsy et al. 2009 low low low low low low low low 
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